In the absence of new targeted therapies, conventional chemotherapy remains the mainstay of treatment with suboptimal outcomes. Recent discoveries have revealed that TNBC is a heterogeneous disease entity at the clinical, histological and molecular levels. Advanced technologies, such as next generation sequencing, have led to the identification of several molecular characteristics including the inactivation of the BRCA pathway, MAP/ERK kinase (MEK) and Phosphatidylinositol-3-Kinase (PI3K) pathway activation, high rates of Tumor Protein p53 (TP53) mutation, high activation of MYC, loss of retinoblastoma protein (RB1), enrichment for androgen receptor (AR) and the AR gene. 1, 3, 4 In addition, several potentially targetable amplifications or deletions, including immune checkpoints Programmed Death-1 (PD1) and Programmed death-ligand 1 (PDL1), have also been identified. 5 These molecular features have allowed the development of promising therapeutic agents such as DNAdamaging agents, AR inhibitors and immune checkpoint inhibitors.
The objective of this article is to review the ongoing effort to identify subsets of TNBC as well as explore the promising therapeutic strategies that target them.
favorable outcomes in terms of likelihood of progression, available therapeutic options and overall survival (OS). It affects more often women under 40 years of age with higher incidence among African American and Hispanic women compared with other breast cancer subtypes. [6] [7] [8] [9] Neoadjuvant studies have suggested that women with TNBC are more sensitive to initial anthracyclines and taxanes compared with other breast cancer subtypes, with clinical response rates of up to 85% and pathologic complete response (pCR) rates of 30-40%. 10 Although patients who achieve a pCR have a better prognosis, the vast majority of patients with TNBC have residual disease after preoperative chemotherapy and usually present with rapid disease progression in the following 3-5 years. [11] [12] [13] [14] [15] To date there are no predictive factors that identify subsets of patients with TNBC who will ultimately achieve pCR.
Triple negative tumors present a distinctive pattern of relapse, with a higher risk of developing distant metastasis and death compared with other breast cancer subtypes. [16] [17] [18] [19] These tumors have a predilection for visceral, lung and brain metastasis compared with luminal breast cancers that favor relapses in bone and skin. [20] [21] [22] Harrell and colleagues reported a higher incidence of brain and lung metastases in basal-like (BL) and claudin-low breast tumors (both commonly triple negative), 23 with approximately 50% of brain relapses occurring in patients with advanced TNBC. 24 The histologic heterogeneity of TNBC TNBC is diagnosed immunohistochemically as breast tumors that do not overexpress ER, PR or HER2. However, the cut off used to define estrogen and PR negativity has changed over time, resulting in a discordance in the definitions used in the literature (<10% versus <1%). The current definition established by the American College of Pathology, the American Society of Clinical Oncology and the St Gallen guidelines, recently used a cut off of less than 1% to define estrogen and progesterone negative tumor; whereas, HER2 negativity is defined as either immunohistochemistry (IHC) expression of 0-1+ or lack of gene amplification (Fluorescence In Situ Hybridization (FISH), 2.0). [25] [26] [27] Consequently, endocrine therapy is currently prescribed for patients with ER expression of at least 1% in all stages of breast cancer. This has resulted in a subset of patients (ER expression 1-10%) who were previously considered ER negative but who under the current recommendations would receive endocrine therapy.
The large majority of TNBC tumors are invasive ductal carcinomas characterized by high histologic grade, poor differentiation, central necrosis, high lymphocytic infiltrate and high proliferation rates. 12, 13 In addition, several other high-grade histologic subtypes of breast cancer including medullary carcinoma, metaplastic carcinoma, adenoid cystic carcinoma and apocrine/histiocytoid carcinoma present with the TNBC phenotype. [28] [29] [30] [31] [32] Molecular heterogeneity of TNBC Molecular profiling has confirmed the heterogeneous nature of TNBC that had already been observed from its clinical behavior. The Cancer Genome Atlas (TCGA) Research Network analyzed primary breast cancers using six platforms, including genomic DNA copy number arrays, messenger RNA arrays, exome sequencing, DNA methylation, microRNA sequencing, and reversephase protein arrays. 4 The most frequent genetic alterations were found in DNA damage-repair genes, including loss of TP53, RB1 and BRCA1 in addition to activation of the PI3K pathway.
It is important to understand the difference between TNBC and the BL phenotype because TNBC is frequently assimilated into the BL molecular phenotype, although these two breast cancer subtypes are not synonymous.
In reality, 75-80% of TNBCs display a BL molecular phenotype on gene expression arrays, and it is identified by a basal epithelial cell gene expression cluster, including high-molecular-weight basal cytokeratin 5/6 (CK5/6), CK14, CK17, epidermal growth factor receptor (EGFR), HER1, B crystallin, vimentin, laminin, integrin-b4, fascin, caveolin 1/2 (CAV1/2), c-Kit, and P-cadherin. Similarly, not all BL tumors are TNBC; and up to 54% of BL cancers do not present the immuno-histochemical phenotype of TNBC. 33, 34 Both BL breast cancer and TNBC show an important overlap with BRCA1-mutated tumors. The prevalence of BRCA1 or two mutations in TNBC is estimated to be between 10% and 20%, 35 and these mutations play a major role in DNA repair as tumor suppressor genes. This specific genomic instability in BRCA-1 carriers may provide specific therapeutic opportunities in journals.sagepub.com/home/tam 495 TNBC. Given the limited clinical usefulness of the BL molecular phenotype, the best strategy is to identify BL tumors using an immunohistochemistry panel of antibodies (ER, HER2, CK5/6 and EGFR HER1). 36, 37 Other molecular markers, that may be targetable, have also been identified by differential gene expression, including several amplifications and deletions. 33, 38 Common amplifications include PIK3CA (49%), KRAS (32%), VEGFR (>30%), BRAF (30%), EGFR (23%) whereas less frequent ones include KIT, MET, FGFR1, FGFR2, PDGFRA and IGFR1. 4 Deletions were also observed in PTEN, INPP4B in addition to deletion of chromosome 5q13-14, which harbors the RASA1 gene and regulates the RAS oncogene. [39] [40] [41] [42] [43] Distinct intrinsic subtypes of TNBC were identified using gene expression and sequencing tools. The study by Lehmann and colleagues analyzed 587 TNBCs by gene expression profiling and has identified six subtypes. 1 The authors identified two BL subtypes (BL1 and BL2), mesenchymal (M), mesenchymal stem-like (MSL), immunomodulatory (IM) and finally a luminal androgen receptor (LAR) with sensitivity to an AR antagonist. BL1 tumors are characterized with high expression of cell cycle and DNA damage response gene expression signatures and BL2 tumors are characterized by enrichment in growth factor signaling and myoepithelial markers. The two mesenchymal subtypes, M and MSL, are characterized by high expression of genes involved in differentiation and growth factor pathways with high sensitivity to dual PI3K/mTOR inhibition and Abl/Src inhibitor dasatinib. 44 This study fostered a major effort to discover and develop new drugs that target specific subtypes of TNBC.
Claudin-low is another less common subtype of TNBC that shows low expression of luminal differentiation markers, low expression of genes involved in tight cell junctions such as E-cadherin, intense immune infiltrate, high enrichment for epithelial-tomesenchymal transition (EMT) markers and stemcell-like features that may be enriched in BRCA pathway alterations. 45, 46 Response to treatment of claudin-low subtype is intermediate between luminal and BL subtypes explained by the high rate of medullary and metaplastic differentiation.
Further classification using combination copy number transcriptome analysis highlights the heterogeneity of TNBC tumors. 47, 48 Therapeutic approaches to TNBC In the absence of new approved targeted therapies, standard chemotherapy is still the mainstay of treatment. The heterogeneity of TNBC has made it difficult to treat unselected patients. As a result there is an ongoing effort to develop more specific targets, and several new targeted treatments and immunotherapeutic drugs are under development.
DNA-damaging chemotherapy and DNA repair targets DNA repair mechanisms play a major role in maintaining the integrity and stability of the genome. BRCA1 and BRCA2 are tumor suppressor genes that are directly involved in homologous recombination-mediated repair of double-stranded breaks. Defects in BRCA1 or BRCA2 genes result in impaired DNA repair by homologous recombination and subsequent genomic instability. 49, 50 As a result, women with germline mutations in these genes are predisposed to hereditary cancer syndromes, including breast and ovarian cancers. Breast cancers arising in BRCA1 germline mutation carriers display a triple-negative phenotype in more than 75% of cases. 51, 52 Understanding DNA repair mechanism defects has allowed the development of new therapeutic approaches in TNBC due to their higher sensitivity to DNA-damaging agents, including platinum salts and poly ADP-ribose polymerase (PARP) inhibitors.
However, sporadic breast cancers have also been associated with various genetic and epigenetic disruptions to BRCA function, leading to impaired homologous repair. These sporadic breast cancers share various phenotypic characteristics with familial BRCA cancers, a concept that has been termed 'BRCAness'. [53] [54] [55] [56] Optimal use of platinum salts in TNBC Platinum salts are non-cell-cycle-specific agents that bind with DNA to form intrastrand crosslinks, thus affecting DNA replication and subsequently inducing apoptosis in cancer cells. The addition of platinum salts to the treatment of TNBC in the neoadjuvant and metastatic setting stems from its proclaimed role in TNBC associated with BRCA1 mutation. The use of platinum appears to be an important therapeutic option in the metastatic setting, where treatments are mainly palliative due to the lack of specific standards for TNBC but even more so in patients who are BRCA positive.
PARP inhibitors. PARP enzymes play a major role in DNA repair mechanisms, specifically in homologous recombination-mediated repair of doublestranded breaks. Any reduction in their activity leads to persistent DNA lesions that subsequently induce apoptosis. As a result, inhibitors of PARP enzymes were developed to target vulnerable cancers with specific DNA-repair deficiency, including TNBC with BRCA1/2 mutations and TNBC with BRCAness phenotype.
Several trials tested the role of PARP inhibitors alone or in combination with chemotherapy in different settings (Table 1) . Olaparib is an orally active PARP inhibitor that has an impressive response rate and favorable toxicity. A phase II study assessed the efficacy, safety, and tolerability of olaparib in women with BRCA1 or BRCA2 mutations and advanced breast cancer. Patients were assigned to two sequential cohorts. The first cohort (n = 27) was given continuous oral olaparib at the maximum tolerated dose (400 mg twice daily), and the second (n = 27) was given a lower dose (100 mg twice daily). Overall responses ranged from 22% (100 mg twice per day) to 41% (400 mg twice per day) with favorable toxicity. 65 Other 66 Based on these impressive results, a phase III study was conducted to evaluate iniparib using the same design. 67 Unfortunately, there was no statistical benefit in terms of PFS and OS. These poor results were explained in part due to its original misclassification as a PARP inhibitor, and the subsequent discovery that iniparib lacked PARP activity. 68, 69 In the neoadjuvant setting, a single-arm phase II trial has showed an important response rate, with iniparib especially in BRCA1/BRCA2 carriers. 70 Similarly, the addition of veliparib and carboplatin to standard neoadjuvant chemotherapy produced an improvement in pCR for patients with TNBC from 26% to 52%, but it is difficult to extract the benefit of veliparib from the benefit of carboplatin. 71 The BROCADE trial is another randomized phase II study that evaluated the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel versus placebo in patients presenting with locally advanced or metastatic BRCA1/BRCA2-mutant breast cancer, with 42.4% of patients who had TNBC. 72 Talazoparib is a novel, dual-mechanism PARP inhibitor that potently inhibits the PARP enzyme and effectively traps PARP on DNA. The phase I trial [ClinicalTrials.gov identifier: NCT01286987] showed an important single-agent antitumor activity in BRCA-mutated breast cancer (ORR 33%). 73 A phase II trial is evaluating the activity of talazoparib in patients with BRCA1/2 wild-type breast cancer using an optimal Simon two-stage design. Patients will be assigned to one of two parallel cohorts. The first cohort (n = 29) includes patients with advanced TNBC with underlying homologous recombination defects as assessed by the HRD assay and the second cohort (n = 29) includes patients with advanced HER2-negative breast cancer with a somatic or germline deleterious mutation in a non-BRCA1/2 HR pathway gene. Eligible patients will receive oral talazoparib (1.0 mg/day, 28-day cycles) until disease progression or unacceptable toxicity [ClinicalTrials.gov identifier: NCT02401347]. 74 An ongoing international phase III trial (EMBRACA) is comparing the safety and efficacy of talazoparib versus physician's choice (capecitabine, eribulin, gemcitabine or vinorelbine) in BRCA-mutation subjects with locally advanced or metastatic breast cancer. The primary objective is PFS and secondary objectives include objective response rate (ORR), OS, and safety [ClinicalTrials.gov identifier: NCT01945775] (Table 1) .
Targeting growth factors. Inhibition of vascular endothelial growth factor (VEGF)
. VEGF is overexpressed in TNBC and has a critical role in proliferation, invasion and metastasis. This is supported by the high proliferative potential of TNBC and has led to the incorporation of antiangiogenic treatments but with limited activity in unselected patients.
In a meta-analysis of three phase III trials of bevacizumab given as first-line therapy in the metastatic setting (E2100, AVADO, RIBBON-1), a pooled analysis of 621 patients with TNBC demonstrated a significant benefit in terms of median PFS (8.1 versus 5.4 months), but not OS. 75 Similar findings were observed in second-line therapy in a subgroup analysis of the RIBBON-2 study, in which bevacizumab showed a benefit in PFS among the TNBC subgroup (6.0 versus 2.7 months for chemotherapy alone; p = 0.0006) but without statistically significant advantage in OS. 76 After mature survival results became available, bevacizumab lost its regulatory approval in metastatic breast cancer in the United States, but continues to be used in other countries. 60, 77 In the neoadjuvant setting, the GeparQuinto showed high rates of pCR when bevacizumab was added to anthracycline/taxane-based chemotherapy, but these findings were not confirmed in the NSABP B-40 trial. 78, 79 Similar disappointments followed with adjuvant trials such as the phase III BEATRICE trial in which bevacizumab failed to show an advantage in OS. 80 Regarding anti-VEGFR tyrosine kinase inhibitors such as sunitinib and sorafenib, they showed an activity in breast cancer in clinical studies with substantial TNBC populations. However, subsequent phase III trials were negative.
In a prospective and randomized phase III study, patients with advanced breast cancer were randomly assigned to receive docetaxel with or without sunitinib as a first-line treatment. Although ORR was significantly higher with the combination compared with monotherapy (55% versus 42%, p = 0.001), the PFS was not different (p = 0.265) and adverse events were also more common with the combination. 81 A randomized phase III trial (SUN 1107) evaluated single-agent sunitinib versus single-agent capecitabine for the treatment of patients with advanced breast cancer after failure of standard treatment, with the primary endpoint of prolonging PFS. The data showed an inferior outcome for the sunitinib versus the capecitabine group. The median PFS was 2.8 versus 4.2 months and median OS was 15.3 versus 24.6 months. Based on these results, the study was thought to be futile and discontinued early. 82 Sorafenib was also evaluated in several trials. A phase II trial, demonstrated that the combination of sorafenib and capecitabine improved PFS in patients with advanced HER2-negative breast cancer (median 6.4 versus 4.1 months; HR 0.58; 95% CI 0.41-0.81; p = 0.001). 83 These results led to a phase III confirmatory study (RESILIENCE trial) in which 537 women with locally advanced or metastatic HER2-negative breast cancer who had received no more than one prior regimen were enrolled. 84 The trial excluded women previously treated with a VEGF receptor inhibitor. Patients received capecitabine at 1000 mg/m 2 twice daily plus sorafenib or placebo 600 mg/day. The study did not meet its primary endpoint, with a median PFS of 5. Inhibition of EGFR. Overexpression of EGFR is well established in TNBC and was reported in over 50% of cases. Although EGFR plays an important role in proliferation and migration, only limited activity was seen with monoclonal antibodies against EGFR. 85 These disappointing results suggested a lack of correlation between EGFR overexpression and the activity of EGFR inhibitors in TNBC.
Patients with TNBC treated with the EGFR inhibitor cetuximab in addition to cisplatin in the phase III trial (BALI-1) reported improved ORR of 20% compared with 10% for those who received cisplatin alone, but the difference was not statistically significant. PFS was also improved from 1.5 to 3.7 months but with nonnegligible toxicity, mainly in the form of rash and neutropenia. 86 Another EGFR inhibitor, panitumumab, was investigated in a single-arm phase II clinical trial including 14 patients with locally advanced and metastatic TNBC, evaluating the combination of weekly paclitaxel, carboplatin and panitumumab. The ORR of the 13 evaluable patients was 46%, while the median time to best response was 2.4 months and the median time to disease progression was 3.6 months. 87 A more recent phase II trial evaluated panitumumab among 71 women with metastatic TNBC in addition to carboplatin and gemcitabine. The median PFS was 4.4 months (95% CI 3.2-5.5 months) with a median follow up of 11 months and the ORR was 42%. Reported toxicity was mainly in the form of rash (70%), fatigue (52%), neutropenia (45%) and thrombocytopenia (45%). 88 Inhibition of FGFR. FGFR1 is amplified in TNBC in approximately 9% of tumors and FGRF2 in 4%. 89 Both of them have a critical role in differentiation, proliferation, resistance to apoptosis and metastasis. Their implication in the cancer process makes them an interesting target for development of new personalized treatments. 89 A small phase II neoadjuvant study including 50 patients with TNBC evaluated the addition of everolimus to weekly paclitaxel followed by anthracycline-based chemotherapy. The everolimus arm was associated with an improved clinical response rate (48% versus 30%), but this was not statistically significant and no benefit was noted in terms of pCR rate. 91 An ongoing randomized phase II trial is testing the efficacy of adding everolimus to weekly paclitaxel plus bevacizumab in the first- Inhibition of C-kit. Several studies have investigated the expression of C-kit in breast cancers and have observed different percentages of expression of 11-31% of BL breast cancers. 1, 99, 100 This overexpression of C-kit implied that these patients might potentially benefit from tyrosine kinase inhibitors (TKIs). However, there is no correlation between the overexpression of C-kit in TNBC and the activating mutations in C-kit and PDGFRA gene. It explains why only a few patients achieve a response to imatinib. 101, 102 A Chinese study that included 171 patients with TNBC has shown 42.1% of C-kit overexpression but only one activating mutation was detected. 103 Further investigations among larger and more heterogeneous populations are required to select patients who can benefit from targeting c-kit in TNBC. Dasatinib is another small molecule that inhibits not only the src and abl kinases but also the C-kit, and could be a potential molecular targeted drug for C-kit-positive TNBC. 104 Inhibition of the JAK2/STAT3 pathway. Janus kinases (JAKs) are tyrosine kinases that activate STAT3 proteins, which are involved in regulation of cell growth, survival, angiogenesis and immunosuppression. The JAK-STAT signaling pathway is frequently deregulated in several cancers, including BL breast cancer, and subsequently may be an effective clinical strategy to treat TNBC. 105 TCGA reports have shown a high rate of JAK2 amplifications among women with TNBC who received preoperative chemotherapy compared with women with primary untreated BL breast cancers. 4 Consequently, inhibition of the JAK pathway could be promising in the subgroup of patients with JAK2-amplifıed residual disease. An ongoing phase II study is evaluating the combination of ruxolitinib with preoperative chemotherapy for triple-negative inflammatory breast cancer Inhibition of notch signaling. Studies have shown the aberrant activation of notch signaling in breast cancer and its involvement in proliferation, apoptosis and cancer stem cell activity. The high expression of Notch signaling pathway components including Jagged1-2, Dll1, Dll3 and Dll4, Notch receptors, and Hes and Hey target genes have been demonstrated in breast cancer. 106 The activation of notch receptor via the interaction between the membrane-bound ligand and notch receptor leads to a conformational change within the negative regulatory region. This results in sequential cleavage by the ADAM17/TACE metalloprotease and γ secretase, which releases the notch intracellular domain (NICD). Finally NICD translocates to the nucleus and then activates the transcriptional process. 107 Based on these findings, the inhibition of Notch signaling may be a promising therapeutic option for patients with TNBC. Preclinical data demonstrated that TNBC xenograft models with NOTCH1 rearrangements, retaining the γ-secretase cleavage site, were associated with high levels of activated NOTCH1 and conferred sensitivity to γ-secretase inhibitors.
A phase II study is evaluating the efficacy and safety of an oral γ-secretase inhibitor PF-03084014 as a single treatment in patients with advanced TNBC, harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of patients with advanced TNBC whose tumor tests negative for genomic alterations in Notch receptors (NA- Recent studies have revealed that a higher level of TILs (>50%) was associated with worse clinicopathologic features, such as higher grade, higher expression of the proliferation marker Ki-67, and positivity of lymph nodes, but paradoxically, it was associated with better pCR in the neoadjuvant setting in addition to improved PFS and OS in the metastatic setting. [121] [122] [123] [124] However, research on gene expression profiling has also revealed that TNBC had higher rates of CD8+ T-cell infiltration, which was predictive of good prognosis. 125 Similarly, intratumoral B cells were found to be associated with favorable outcomes in breast cancer. In contrast, CD4+ T cells, including tumor-associated macrophages and T-regulatory cells, were associated with worse prognosis.
The gene expression analysis of Lehman and colleagues has identified six TNBC subtypes, among them the IM subtype which is composed of immune activated and associated signaling components contributed from both the tumor and the infiltrating lymphocytes. This subtype was associated with better outcome (relapse-free survival) in comparison with other TNBC subtypes. 1 Inhibition of PDL1 with atezolizumab was tested in a phase I trial in patients with metastatic TNBC. Grade 3-4 toxicities were observed in 8% of patients and immune-related adverse events occurred in a minority of patients. The study reported an ORR of 33% in the nine evaluable patients with one complete response and two partial responses. All responses were seen within the first 6 weeks of treatment. 131 A neoadjuvant phase III study with atezolizumab is currently ongoing in patients with locally advanced TNBC undergoing treatment with nabpaclitaxel and carboplatin. The primary endpoint is event-free survival [ClinicalTrials.gov identifier: NCT02620280]. Another phase III randomized trial is evaluating atezolizumab with nab-paclitaxel for first-line treatment of patients with locally advanced or metastatic TNBC [ClinicalTrials.gov identifier: NCT02425891].
Another anti-PDL1 agent avelumab was recently evaluated and the study revealed attractive results in the TNBC subgroup. Avelumab produced an improvement in clinical response among patients with PDL1 expression on immune cells estimated at 44.4% versus 2.6% in the absence of expression. 132 Regarding inhibition of CTLA4, a phase I study is currently evaluating tremelimumab, which is an anti-CTLA4 agent, in patients with advanced solid tumors including breast cancer [ClinicalTrials.gov identifier: NCT02527434]. 
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